On the other hand, prostate-specific antigen (PSA), a widely used biomarker in prostate cancer management, has demonstrated a sensitivity of 0.85 and a specificity of 0.84, both of which are higher than those of G6PD activity. This evidence concerns the gene G6PD and Familial prostate cancer.